Monitoring of modified factor VIII and IX products

S Kitchen; E Gray; K Mertens

doi:10.1111/hae.12423

Monitoring of modified factor VIII and IX products

S Kitchen
, E Gray
, K Mertens

Pharmaceutics

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents.

Original language	English
Pages (from-to)	36-42
Number of pages	7
Journal	Haemophilia
Volume	20 Suppl 4
DOIs	https://doi.org/10.1111/hae.12423
Publication status	Published - 2014

Bibliographical note

Keywords

Animals
Blood Coagulation Tests
Factor IX
Factor VIII
Hemophilia A
Hemophilia B
Humans
Protein Engineering
Recombinant Proteins

Access to Document

10.1111/hae.12423

Embargoed Document

Kitchen_et_al-2014-Haemophilia
Final published version, 109 KB
Embargo ends: 1/01/50

Cite this

@article{62622059572a4a358743de17fa8a410b,

title = "Monitoring of modified factor VIII and IX products",

abstract = "The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents.",

keywords = "Animals, Blood Coagulation Tests, Factor IX, Factor VIII, Hemophilia A, Hemophilia B, Humans, Protein Engineering, Recombinant Proteins",

author = "S Kitchen and E Gray and K Mertens",

note = "{\textcopyright} 2014 John Wiley \& Sons Ltd.",

year = "2014",

doi = "10.1111/hae.12423",

language = "English",

volume = "20 Suppl 4",

pages = "36--42",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Monitoring of modified factor VIII and IX products

AU - Kitchen, S

AU - Gray, E

AU - Mertens, K

PY - 2014

Y1 - 2014

N2 - The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents.

AB - The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents.

KW - Animals

KW - Blood Coagulation Tests

KW - Factor IX

KW - Factor VIII

KW - Hemophilia A

KW - Hemophilia B

KW - Humans

KW - Protein Engineering

KW - Recombinant Proteins

U2 - 10.1111/hae.12423

DO - 10.1111/hae.12423

M3 - Article

C2 - 24762273

SN - 1351-8216

VL - 20 Suppl 4

SP - 36

EP - 42

JO - Haemophilia

JF - Haemophilia

ER -

Monitoring of modified factor VIII and IX products

Abstract

Bibliographical note

Keywords

Access to Document

Embargoed Document

Fingerprint

Cite this